, Tracking Stock Market Picks
Enter Symbol:
Medicinova, Inc. (MNOV) [hlAlert]

up 75.73 %

Medicinova, Inc. (MNOV) rated Buy with price target $6 by Ladenburg Thalmann

Posted on: Friday,  Jan 4, 2013  1:25 PM ET by Ladenburg Thalmann

Ladenburg Thalmann rated Buy Medicinova, Inc. (NASDAQ: MNOV) on 01/04/2013, when the stock price was $1.69. Since
then, Medicinova, Inc. has gained 75.74% as of 08/27/2015's recent price of $2.97.
If you would have followed this Ladenburg Thalmann's recommendation on MNOV, you would have gained 75.73% of your investment in 965 days.

Medicinova, Inc., incorporated in September 2000, is a biopharmaceutical company focused on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the United States market. Through strategic alliances primarily with Japanese pharmaceutical companies, the Company is developing a portfolio of clinical and preclinical product candidates. Medicinova has acquired licenses to eight compounds for the development of 10 product candidates. Its development pipeline includes eight programs which have been in clinical development for the treatment of asthma, acute exacerbations of asthma, multiple sclerosis, or MS, interstitial cystitis (IC), solid tumor cancers, Generalized Anxiety Disorder/insomnia, preterm labor and urinary incontinence. The Company is focused on the development of two prioritized assets in its development pipeline: MN-221 for the treatment of status asthmaticus, and MN-166 for the treatment of MS.

Our Research Department takes a fresh, critical approach to analyzing primary sources and developing proprietary research. Many individuals, institutions, portfolio managers and hedge fund managers, on all levels, have been neglected by brokerage firms ignoring the demands for unbiased research. Ladenburg Thalmann provides a superior branded in-depth research product geared only to action-oriented investment ideas. Ladenburg Thalmann’s proprietary equity research tries to uncover crucial information before the rest of the Street. Our analysts concentrate on uncovered and under-covered stocks and have a small to mid-cap focus. We will not shy away from large cap names as long as we can bring value to our clients through timely, differentiated ideas.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/4/2013 1:25 PM Buy
1.69 6.00
as of 12/13/2013
1 Week up  3.98 %
1 Month up  8.29 %
3 Months down  -1.67 %
1 YTD up  39.05 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy